# A client with inflammatory bowel disease is taking the immunosuppressant methotrexate. Which laboratory test must be monitored on a regular basis?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=491184  
> language: ko  
> subject: Nursing

## 문제

A client with inflammatory bowel disease is taking the immunosuppressant methotrexate. Which laboratory test must be monitored on a regular basis?

## 보기

1. Electroencephalogram
2. Pulmonary function test
3. Echocardiogram
4. Complete blood count **✔ 정답**
5. Arterial blood gas analysis

**정답: 4**

## 해설

Methotrexate can cause life-threatening bone marrow suppression (decreased white blood cells, red blood cells, and platelets), so monitoring with a complete blood count (CBC) is essential.

## 심화 해설

Key nursing concept: Monitoring the client receiving methotrexate (MTX)

Methotrexate is an immunosuppressant used not only for inflammatory bowel disease but also for a variety of autoimmune conditions such as rheumatoid arthritis. It is an antimetabolite that inhibits cell division, so it has its strongest effect on rapidly dividing cells. This is how it reduces joint inflammation, but it also suppresses the hematopoietic stem cells of the bone marrow—normal cells that divide rapidly—and can therefore cause myelosuppression.

When myelosuppression occurs, production of all three major blood components—white blood cells, red blood cells, and platelets—declines. A drop in white blood cells (leukopenia) raises the risk of infection; a drop in platelets (thrombocytopenia) raises the risk of bleeding; and a fall in hematocrit (HCT), an index of red blood cells, can produce fatigue and pallor from anemia. In addition, because methotrexate is metabolized by the liver, hepatotoxicity is another major adverse effect. Detecting these toxicities early during therapy is therefore of the highest importance.

Why the complete blood count (CBC)?

The supporting evidence clearly shows that regular monitoring of the complete blood count (CBC) and liver function tests (LFTs) is the standard of care for clients taking methotrexate [1]. One study followed clients receiving methotrexate for liver values such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) along with white blood cell count (WBC), hematocrit (HCT), mean corpuscular volume (MCV), and platelet count (PLT) [1]. All of these values are basic parameters included in a CBC and liver function panel.

Another study analyzed changes in hematologic parameters over the first 12 weeks after starting methotrexate and evaluated how those changes correlated with treatment response and disease activity [2]. This suggests that beyond simply causing toxicity, changes in blood cell counts themselves can serve as an important predictor of a client's response to the drug. In other words, tracking WBC, platelet, and hemoglobin/hematocrit trends with a CBC provides the evidence base for the nursing interventions needed to detect myelosuppression—a serious adverse effect—early and to adjust the dose or hold the drug when indicated.

Rationale for each option and nursing judgment

*   1. Electroencephalogram (EEG): The main toxicities of methotrexate involve the bone marrow and liver; direct central nervous system toxicity is not a priority monitoring parameter.

*   2. Pulmonary function test (PFT): Methotrexate can rarely cause interstitial pneumonitis, but this test is performed diagnostically when symptoms appear. The top priority for routine follow-up is assessment for myelosuppression and hepatotoxicity.

*   3. Echocardiography: Significant cardiac toxicity has not been reported with methotrexate, so this is not a routine follow-up test.

*   4. Complete blood count (CBC): Correct. It evaluates all blood cell lines produced in the bone marrow and allows early detection of drug-induced myelosuppression. The evidence also identifies WBC, HCT, and PLT as key monitoring parameters [1][2].

*   5. Arterial blood gas analysis (ABG): This test evaluates pulmonary gas exchange and acid–base balance and is not related to routine monitoring of methotrexate adverse effects.

Therefore, when caring for a client on methotrexate, the nurse should keep the scheduled blood draws and closely assess whether WBC, platelet, and hemoglobin values fall below normal limits (myelosuppression) and whether AST/ALT are rising (hepatotoxicity). If the WBC falls below 3,000/mm³ or the platelet count falls below 100,000/mm³, the risk of infection and bleeding rises sharply, so the nurse must notify the provider immediately and verify whether the drug should be held.References (research sources)

- [1]Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs During Methotrexate Therapy.Research articleSimko S, Zhang R, Mukherjee S, Bajaj P, Bermas BL. (2026) · DOI: 10.1002/acr.80121

- [2]Retrospective Analysis of Hematological Parameter Changes in DMARD-Naive Rheumatoid Arthritis Patients Treated with Methotrexate: Correlation with Disease Activity and Treatment Outcomes.Research articleImrak ED, Aktas İ. (2026) · DOI: 10.3390/biomedicines14030625

## 임상 시나리오

Monitoring the client taking methotrexateRequired routine labs and surveillance for adverse effects
Because clients taking methotrexate are at risk for myelosuppression, a complete blood count should be obtained regularly to track changes in white blood cell, platelet, and hemoglobin values.

To monitor for drug-induced hepatotoxicity, liver function tests are also obtained, checking for elevations in ALT and AST.

AlertTeach the client the signs of myelosuppression—fever and sore throat (suggesting low WBCs), easy bruising and gum bleeding (suggesting low platelets), and severe fatigue (suggesting anemia)—and instruct the client to report them to the health care team immediately.

## 핵심 개념

- **Myelosuppression** — A state in which hematopoietic stem cell function in the bone marrow is suppressed, reducing production of white blood cells, red blood cells, and platelets.
- **Complete blood count** — A basic blood test that evaluates the number and morphology of white blood cells, red blood cells, and platelets.
- **Methotrexate** — An antimetabolite immunosuppressant that inhibits cell division, used to treat inflammatory bowel disease and autoimmune disorders.

## 같은 주제 문제

- [Thoracentesis](https://mymerci.kr/pages/nclex_q.php?qn_id=491171)
- [A client is admitted with an acute exacerbation of chronic obstructive pulmonary disease (…](https://mymerci.kr/pages/nclex_q.php?qn_id=491174)
- [A 72-year-old woman is brought to the emergency department with vomiting and diarrhea. She…](https://mymerci.kr/pages/nclex_q.php?qn_id=491176)
- [Which arrhythmia is represented by the following ECG tracing?](https://mymerci.kr/pages/nclex_q.php?qn_id=491177)
- [A 58-year-old man is admitted to the unit with a 3-day history of decreased urine output a…](https://mymerci.kr/pages/nclex_q.php?qn_id=491178)
- [The picture below shows a surgical position. Which type of surgery requires this position?](https://mymerci.kr/pages/nclex_q.php?qn_id=491179)
- [A client who experiences epigastric pain when the stomach is empty has been prescribed cim…](https://mymerci.kr/pages/nclex_q.php?qn_id=491180)
- [Which nursing problem should the nurse address first?](https://mymerci.kr/pages/nclex_q.php?qn_id=491181)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._